RxDoctor Payments Data

Michael Weisbruch, MD

Internal Medicine · Niceville, FLNPI 1114286879

Payments from drug & device makers

$1,668in general payments, 2019–2025

Across 73 payments — averaging $22.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$281
  • Novo Nordisk$164
  • Amgen$163
  • Nevro Corp.$151
  • Atricure, Inc.$149
  • Lilly USA, LLC$113
  • plus $648 from 14 others

What the payments were for

  • Food & beverage$1,668100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,668 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$1,397,135
Medicare patients
1,007
Services billed
18,385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin35$47,818
MounjaroTirzepatide38$45,742
OzempicSemaglutide21$34,806
TrulicityDulaglutide18$18,175
FarxigaDapagliflozin Propanediol13$15,223
EntrestoSacubitril/Valsartan14$14,409
Rosuvastatin Calcium125$1,776
Bupropion XlBupropion Hcl25$1,027
Levothyroxine Sodium91$874
Losartan Potassium98$840
Ezetimibe39$750
Atorvastatin Calcium66$629
Telmisartan11$571
Metoprolol Succinate31$522
Famotidine39$490

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$113$63,91856 claims
Boehringer IngelheimJardiance$56$47,81835 claims
Novo NordiskOzempic$164$34,80621 claims
AstraZenecaFarxiga$281$15,22313 claims
NovartisEntresto$75$14,40914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Niceville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →